Company updateMoneycontrol
Glenmark shares rise over 2% on US drug filing
Positive+403 sources
GreyOak summary
Glenmark Pharmaceuticals shares rallied 2.53% after its innovation arm, Ichnos Glenmark Innovation, filed an Investigational New Drug application with the US FDA for ISB 2301. This experimental trispecific antibody targets solid tumours like breast and lung cancer. The company plans to begin Phase 1 human trials in 2027 following favourable preclinical results.
What it affects
- Glenmark PharmaceuticalsGLENMARKPositive +40
Shares rose 2.53% on US FDA filing.Rolling sentiment Neutral +7
Source
Read the original at MoneycontrolMore Glenmark Pharmaceuticals news
- Stocks to Watch Today: Ashoka Buildcon, Prestige Estates, Advait Energy, Glenmark, IIFL Finance, NDR Auto, RITES…Moneycontrol · Order win ·
- Glenmark launches generic Inlyta for kidney cancer in USEconomic Times · Company update ·
- Glenmark shares rise after US arm launches cancer therapyCNBC-TV18 · Stock view ·